Cosmos Health (COSM) Projected to Post Earnings on Friday

Cosmos Health (NASDAQ:COSM) is projected to post its results after the market closes on Friday, April 10th. Analysts expect Cosmos Health to post earnings of ($0.04) per share and revenue of $18.8210 million for the quarter.

Cosmos Health Stock Up 0.6%

Shares of COSM stock opened at $0.30 on Thursday. Cosmos Health has a 12 month low of $0.28 and a 12 month high of $1.32. The firm has a market cap of $11.23 million, a PE ratio of -0.40 and a beta of 5.33. The stock has a 50 day moving average of $0.37 and a 200-day moving average of $0.60. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Insider Activity

In other news, CEO Grigorios Siokas acquired 388,532 shares of the stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of $0.37 per share, for a total transaction of $143,756.84. Following the completion of the transaction, the chief executive officer owned 8,861,914 shares in the company, valued at approximately $3,278,908.18. This trade represents a 4.59% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders purchased 1,730,120 shares of company stock worth $763,663 in the last quarter. Insiders own 25.10% of the company’s stock.

Institutional Trading of Cosmos Health

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd increased its position in shares of Cosmos Health by 52.1% during the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares during the period. Citadel Advisors LLC increased its position in shares of Cosmos Health by 133.1% during the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after purchasing an additional 241,775 shares during the period. 12.61% of the stock is currently owned by institutional investors.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.